Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer.

PURPOSE To retrospectively determine the sensitivity and specificity of breast-specific gamma imaging (BSGI) for the detection of breast cancer by using pathologic results as the reference standard. MATERIALS AND METHODS This study was Institutional Review Board approved and Health Insurance Portability and Accountability Act compliant. Informed consent was obtained for participants who were not imaged as part of their clinical protocol but were participating in other Institutional Review Board-approved studies that used BSGI. A retrospective review of 146 women (aged 32-98 years) undergoing BSGI and breast biopsy was performed. Patients underwent BSGI with intravenous injection of 30 mCi (1110 MBq) of technetium 99 ((99m)Tc)-sestamibi and were imaged in craniocaudal and mediolateral oblique projections. Study images were assigned scores, and scores were classified as positive (focal increased radiotracer uptake) or negative (no uptake or scattered heterogeneous physiologic uptake) and compared with biopsy results. The sensitivity, specificity, and positive and negative predictive values were determined. RESULTS In 146 patients, 167 lesions underwent biopsy, of which 83 (16 ductal carcinoma in situ [DCIS] and 67 invasive cancers) were malignant. Of 84 nonmalignant lesions, 82 were benign and two showed atypical histologic results (one atypical lobular hyperplasia and one lobular carcinoma in situ). BSGI helped detect cancer in 80 of 83 malignant lesions with a sensitivity of 96.4% (95% confidence interval [CI]: 92%, 99%) and correctly identified 50 of 84 nonmalignant lesions as negative for cancer with a specificity of 59.5% (95% CI: 49%, 70%). The positive predictive value for 80 of 114 malignant lesions with a BSGI examination with findings positive for cancer was 68.8% (95% CI: 60%, 78%) and the negative predictive value for 50 of 53 nonmalignant lesions was 94.3% (95% CI: 88%, 99%). The smallest invasive cancer and DCIS detected were both 1 mm. BSGI helped detect occult cancer not visualized at mammography or ultrasonography in six patients. CONCLUSION BSIG has high sensitivity (96.4%) and moderate specificity (59.5%) helping detect breast cancers.

[1]  G. de Vincentis,et al.  99mTc-MIBI prone scintimammography in patients with high and intermediate risk mammography. , 1997, Anticancer research.

[2]  C A Kelsey,et al.  Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. , 1998, Radiology.

[3]  Gina Caravaglia,et al.  Scintimammography with dedicated breast camera detects and localizes occult carcinoma. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  H. Biersack,et al.  Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging , 1996, European Journal of Nuclear Medicine.

[5]  N. Hylton,et al.  Magnetic resonance imaging of the breast prior to biopsy. , 2004, JAMA.

[6]  M. Kır,et al.  Clinical Experience with Tc‐99m MIBI Imaging in Patients with Malignant Tumors Preliminary Results and Comparison with TI‐201 , 1992, Clinical nuclear medicine.

[7]  T. M. Kolb,et al.  Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. , 2002, Radiology.

[8]  M. Greco,et al.  Prone scintimammography in patients with non-palpable breast lesions. , 1996, Anticancer research.

[9]  I. Mena,et al.  Prone scintimammography in patients with suspicion of carcinoma of the breast. , 1994, Journal of the American College of Surgeons.

[10]  S. Ilgan,et al.  99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. , 1999, Nuclear medicine communications.

[11]  Tc‐99m Sestamibi Scintimammography for the Evaluation of Breast Masses in Patients with Radiographically Dense Breasts , 1999, The breast journal.

[12]  S. Gündoğdu,et al.  The Value of Scintimammography in Reduction Mammaplasties: A Preliminary Study , 2003, Aesthetic Plastic Surgery.

[13]  J. Hanley,et al.  Statistical analysis of correlated data using generalized estimating equations: an orientation. , 2003, American journal of epidemiology.

[14]  M. O’Connor,et al.  Molecular Breast Imaging: A New Technique Using Technetium Tc 99m Scintimammography to Detect Small Tumors of the Breast , 2005 .

[15]  Javier Villanueva-Meyer,et al.  (99m)Tc sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study. , 2002, Radiology.

[16]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[17]  A. Brandes,et al.  Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer , 2001, European Journal of Nuclear Medicine.

[18]  Rachel F Brem,et al.  High-resolution scintimammography: a pilot study. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  I. Khalkhali,et al.  Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. , 1998, Journal of the National Cancer Institute.

[20]  G De Vincentis,et al.  A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. , 1997, Anticancer research.

[21]  Rachel F Brem,et al.  Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. , 2005, Radiology.

[22]  R. Taillefer.  Clinical applications of 99mTc-sestamibi scintimammography. , 2005, Seminars in nuclear medicine.